SpeeDx Appoints Jeremy Stackawitz as CEO

Jeremy Stackawitz, CEO, SpeeDx ● Photo Credit: SpeeDx

SYDNEY, October 25, 2024 (VSNewsNetwork.com) – SpeeDx, a biohealth company specializing in molecular diagnostic solutions, has announced the appointment of Jeremy Stackawitz as Chief Executive Officer. With over 25 years of leadership experience in the life sciences and diagnostics sectors, Stackawitz will focus on expanding the company’s commercialization, regulatory activities, and partnerships in key markets, including the United States.

"We are thrilled to welcome Jeremy as the new CEO of SpeeDx at a pivotal time for the company. Jeremy’s proven success in scaling businesses globally, along with his deep understanding of the diagnostics landscape, make him the ideal leader to guide our next phase of growth. With cutting-edge multiplexing technology, SpeeDx has the potential to transform testing, and we’re excited to see Jeremy lead the charge in expanding our global footprint", said Jonathan O. Clark, Chairman of the SpeeDx Board.

Stackawitz previously served as CEO of Senzo, where he oversaw the company’s growth and product expansion. He also held leadership roles at Quotient, where he was helped in secure FDA product approvals and lead the company through an IPO. Stackawitz’s background includes positions at McKinsey & Company and Johnson & Johnson. He holds a bachelor's degree from Dartmouth College and an MBA in Healthcare Management from The Wharton School.

"I am honored to join SpeeDx to help accelerate the company’s trajectory at such an exciting time of expansion. SpeeDx’s proprietary PlexPlus® PCR technology is revolutionizing the diagnostics industry by delivering faster, more cost-effective, and comprehensive infectious disease testing. I look forward to building on the company’s strong foundation and working alongside the talented team to continue advancing our global impact and improving patient outcomes worldwide", said Stackawitz.

Founded in 2009, SpeeDx focuses on molecular diagnostic solutions, particularly in infectious disease management. The company’s real-time PCR technology supports improved patient management by detecting infectious disease pathogens and antimicrobial resistance markers.

For more information, visit plexpcr.com.

Source: SpeeDx